0000950170-23-068795.txt : 20231207 0000950170-23-068795.hdr.sgml : 20231207 20231207160517 ACCESSION NUMBER: 0000950170-23-068795 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231130 FILED AS OF DATE: 20231207 DATE AS OF CHANGE: 20231207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Higgins Michael J CENTRAL INDEX KEY: 0001478521 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38787 FILM NUMBER: 231472378 MAIL ADDRESS: STREET 1: C/O GENOCEA BIOSCIENCES, INC. STREET 2: 100 ACORN PARK DRIVE, 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyclerion Therapeutics, Inc. CENTRAL INDEX KEY: 0001755237 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831895370 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 301 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-621-7722 MAIL ADDRESS: STREET 1: 301 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 3 1 ownership.xml 3 X0206 3 2023-11-30 0 0001755237 Cyclerion Therapeutics, Inc. CYCN 0001478521 Higgins Michael J C/O CYCLERION THERAPEUTICS, INC. 245 FIRST STREET, 18TH FLOOR CAMBRIDGE MA 02142 true false false false Common Stock 21650 D Prior to becoming a Reporting Person, Mr. Higgins held 1,650 shares of common stock of Cyclerion Therapeutics, Inc. On November 30, 2023, the Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan, of which 2,500 of these shares vest immediately and the remaining 17,500 shares vest ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. /s/ Michael Higgins 2023-12-07